Security readout for executives and security teams
Plain-English summary
This flaw lets an unauthenticated network user reach sensitive Agilia Link+ endpoints. In plain terms, a person who can connect to the affected system may be able to perform critical actions or change important configuration without logging in.
Executive priority
Treat as high priority for healthcare environments using Agilia Link+. The business risk is unauthorized changes to a medical device connectivity component, with potential confidentiality, integrity, and availability impact. Prioritize asset discovery, vendor guidance, and network restriction.
Technical view
CVE-2021-23233 is an improper access control issue in Fresenius Kabi Agilia Link+ v3.0 and prior. Sensitive endpoints do not require authentication material such as a session cookie. CVSS 3.1 is 7.3, with network attack vector, low complexity, no privileges, and no user interaction.
Likely exposure
Exposure is most likely where Agilia Link+ v3.0 or prior is reachable over a network by untrusted users or broadly accessible internal segments. The provided sources do not identify specific deployment patterns, internet exposure counts, or compensating controls.
Exploitation context
The source bundle does not show CISA KEV listing or active exploitation evidence. The issue is still serious because exploitation requires network reachability, no credentials, and no user interaction, according to the CVSS vector and description.
Researcher notes
Evidence is limited to the CVE description, CVSS data, CWE-284 classification, affected product statement, and CISA advisory reference. Do not assume other Fresenius Kabi products are affected. No exploit maturity, patch version, or field exploitation details are provided in the bundle.
Mitigation direction
- Identify all Agilia Link+ systems and confirm whether versions are v3.0 or prior.
- Review Fresenius Kabi and CISA guidance before applying product-specific fixes.
- Restrict network reachability to approved clinical engineering and device-management paths.
- Monitor for unexpected configuration changes or sensitive endpoint access attempts.
- Document any interim controls and residual risk for clinical operations leadership.
Validation and detection
- Inventory Agilia Link+ assets and record version, network segment, and ownership.
- Verify unauthenticated users cannot access sensitive administrative or configuration functions.
- Review access logs for unauthenticated requests to sensitive endpoints.
- Confirm remediation status against the CISA advisory and vendor instructions.
- Re-test after changes without using disruptive actions on clinical systems.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CWE-284: Authorization and privilege behavior lookup
Authorization weaknesses can support privilege escalation and valid-account review, depending on exploit path. Open the exact CWE lookup page first, then review the ATT&CK searches from that MITRE weakness context. This is a Glexia lookup hint, not an official ATT&CK mapping.
Open ATT&CK lookupCVE-2021-23233 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- High
- CVSS
- 7.3 (3.1)
- Known Exploited
- No
- Published
Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
CVSS vector scores
1 official scoreWe collect every scored CVSS vector available in the official CNA and ADP containers. When more than one version is present, the table keeps the source vectors side by side instead of collapsing them into the highest score.
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L3.93.4Primary CVE scoreVulnerability scoring details
Base CVSS 3.1 score
7.3HighVector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
Source materials
- CVE List V5 sourceCVE List V5
- https://www.cisa.gov/uscert/ics/advisories/icsma-21-355-01CVE reference · x_refsource_MISC
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.
Improper Access Control
Improper Access Control represents a recurring weakness pattern that can create exploitable paths when design, validation, or implementation controls are missing.